The cancer diagnostics market is surging, with an overall revenue growth expectation of hundreds of billions of dollars within the next eight years. The market is expected to grow to $257 billion by 2030, more than double the $124.9 billion valuation in 2021.
Labcorp Strengthens Oncology Leadership Position With the Addition of Personal Genome Diagnostics, a Provider of Comprehensive Liquid Biopsy and Tissue-Based Genomic Products and Services
Labcorp (NYSE: LH), a leading global life sciences company, today announced that it has entered into a definitive agreement to acquire Personal Genome Diagnostics Inc. (PGDx), a leader in cancer genomics with a portfolio of comprehensive liquid biopsy and tissue-based products.
Cancer genomics company Personal Genome Diagnostics Inc. (PGDx) secured $103 million in a Series C financing round. Proceeds from the financial infusion will be used to expand the company’s tissue-based and liquid biopsy portfolio and its global commercial footprint to support growth.
Personal Genome Diagnostics Appoints Megan Bailey as Chief Executive Officer BALTIMORE, MD, (April 21, 2020) – Personal Genome Diagnostics Inc. (PGDx), a leader in cancer genomics, appointed Megan Bailey as [….]